CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.

Department of Molecular and Cellular Pharmacology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, United States
Blood (Impact Factor: 9.78). 07/2013; DOI: 10.1182/blood-2013-01-481713
Source: PubMed

ABSTRACT Primary effusion lymphoma (PEL) is an aggressive subtype of non-Hodgkin lymphoma (NHL) characterized by short survival with current therapies, emphasizing the urgent need to develop new therapeutic approaches. Brentuximab vedotin (SGN-35) is an anti-CD30 monoclonal antibody (cAC10) conjugated by a protease-cleavable linker to a microtubule-disrupting agent monomethyl auristatin E (MMAE). Brentuximab vedotin is an effective treatment for relapsed CD30-expressing Classical Hodgkin and systemic anaplastic large cell lymphomas. Herein, we demonstrated that PEL cell lines and primary tumors express CD30 and thus may serve as potential targets for brentuximab vedotin therapy. In vitro treatment with brentuximab vedotin decreased cell proliferation, induced cell cycle arrest and triggered apoptosis of PEL cell lines. Furthermore, in vivo brentuximab vedotin promoted tumor regression and prolonged survival of mice bearing previously reported UM-PEL-1 tumors as well as UM-PEL-3 tumors derived from a newly established and characterized KSHV and EBV positive PEL cell line. Overall, our results demonstrate for the first time that brentuximab vedotin may serve as an effective therapy for PEL and provide strong preclinical indications for evaluation of brentuximab vedotin in clinical studies of PEL patients.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Primary effusion lymphoma (PEL) is a rare and aggressive B-cell non-Hodgkin's lymphoma that usually presents with malignant effusions without tumor masses. An extracavitary or solid variant of PEL has also been described. Human herpes virus 8/Kaposi sarcoma-associated herpes virus (HHV-8/KSHV) is universally associated with the pathogenesis of PEL. More than 70% of cases occur with concurrent Epstein-Barr virus infection, but its relation to the pathogenesis is unknown. Patients are found in the context of immunosuppressive states (HIV-1 infection, post-organ transplantation). PEL is usually treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like chemotherapy with antiretroviral therapy if HIV-1 is positive. However, it is generally resistant to chemotherapy with a short median survival of less than 6 months. The optimal treatment for PEL has not been established yet. More intensive chemotherapy, such as dose-adjusted EPOCH (DA-EPOCH; etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin) and CDE (cyclophosphamide, doxorubicin, etoposide) are expected to show a favorable prognosis. Recently, the molecular steps in KSHV/HHV-8-driven oncogenesis have begun to be revealed, and molecular targeting therapies such as proteasome, NF-κB, cytokines and surface antigens would provide evidence for their clinical use.
    08/2014; 3(3):65-74. DOI:10.5582/irdr.2014.01010
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite the introduction of highly active antiretroviral therapy or combination antiretroviral therapy (HAART and cART, respectively) patients infected with HIV might develop certain types of cancer more frequently than uninfected people. Lymphomas represent the most frequent malignancy among patients with HIV. Other cancer types that have increased in these patients include Kaposi sarcoma, cancer of the cervix, anus, lung and liver. In the post-HAART era, however, patients with HIV have experienced a significant improvement in their morbidity, mortality and life expectancy. This Review focuses on the different types of lymphomas that generally occur in patients with HIV. The combination of cART and antineoplastic treatment has resulted in remarkable prolongation of disease-free survival and overall survival among patients with HIV who develop lymphoma. However, the survival in these patients still lags behind that of patients with lymphoma who are not infected with HIV. We also provide an update of epidemiological data, diagnostic issues, and strategies regarding the most-appropriate management of patients with both HIV and lymphomas.
    Nature Reviews Clinical Oncology 03/2014; DOI:10.1038/nrclinonc.2014.31 · 15.03 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although some haematologic diseases such as Hodgkin lymphoma and aggressive lymphoma yield high response rates and acceptable overall survival in first-line treatment, relapse is still a challenge particularly in those patients not eligible for transplant. In acute leukaemias, the prognosis remains poor in general with standard chemotherapy, thus stressing the need for efficient alternate therapies.In recent years, biological anticancer agents comprising mAbs, small targeted molecules or more recently bispecific T-cell engaging molecules or chimeric antigen receptors have been developed in haematologic diseases. This review examines the recent advances in biotherapies in the fields of acute leukaemias, aggressive lymphoma, Hodgkin lymphoma and chronic lymphatic leukaemia.Most biological anticancer agents are currently developed in the setting of relapsed or refractory disease. Some of them however are under development or are already used in first-line therapy wherein they have improved the prognosis of haematology patients.
    Current opinion in oncology 03/2014; DOI:10.1097/CCO.0000000000000079 · 3.76 Impact Factor